Clearwater Paper Corp. 10-Q Summary: Q3 2024
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024. Clearwater Paper Corporation (CLW) is a manufacturer of bleached paperboard. The reporting period is defined by two major strategic transactions: the acquisition of a paperboard facility in Augusta, Georgia (closed May 1, 2024), and the sale of its consumer products (tissue) division to Sofidel America (agreed July 21, 2024; closed November 1, 2024). Consequently, the tissue division is reported as discontinued operations for all periods presented.
Key Financial Metrics
| Metric (in millions) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Sales (Continuing) | $393.3 | $278.9 | $996.5 | $867.4 |
| Net Income (Loss) | $5.8 | $36.6 | $(2.8) | $90.1 |
| Income from Continuing Ops | $(10.7) | $14.9 | $(54.4) | $51.4 |
| Income from Discontinued Ops | $16.6 | $21.7 | $51.6 | $38.8 |
| Adjusted EBITDA (Continuing) | $20.2 | $32.6 | $25.9 | $107.1 |
| Cash and Equivalents | $35.5 | $110.2 | $35.5 | $110.2 |
| Total Debt (Gross) | $1,158.1 | $445.0 | $1,158.1 | $445.0 |
| Operating Cash Flow (9M) | $96.5 | $125.0 | $96.5 | $125.0 |
Material Changes vs. Prior Period
- Revenue Growth: Continuing operations sales increased 41% in Q3 and 15% for the nine months, driven primarily by the inclusion of the Augusta acquisition. However, this volume growth was offset by price decreases and a less favorable product mix.
- Profitability Decline: Continuing operations swung from a profit of $14.9M in Q3 2023 to a loss of $10.7M in Q3 2024. Gross margin declined 41% year-over-year due to price reductions and higher costs associated with a planned maintenance outage at the Lewiston, Idaho facility.
- Debt Expansion: Total debt increased significantly from $445.0 million to $1,158.1 million to fund the $708.2 million Augusta acquisition. Interest expense for the nine months ended September 30, 2024, rose to $24.0 million from $7.9 million in the prior year.
- Discontinued Operations: The tissue division generated $16.6 million in net income for Q3 2024. The sale of this division closed on November 1, 2024, for $1.06 billion.
Guidance, Outlook, and Risks
- Capital Allocation: Proceeds from the tissue division sale were used to pay off all outstanding debt except the 2020 Notes. The Board approved a new $100 million share repurchase authorization in October 2024.
- Outlook: Management expects cash flows from operations and borrowing capacity to be adequate for the next 12 months. Capital expenditures for 2024 are expected to be between $100 million and $120 million.
- Risks: Key risks include integration challenges with the Augusta facility, potential stockholder litigation regarding the tissue sale, and the ability to service increased debt obligations. The company faces competitive pricing pressures and cyclical industry conditions.
- Unusual Items: "Other operating charges" for the nine months included $13.9 million in acquisition-related costs and $5.7 million in integration costs. A $10.5 million insurance recovery was received in Q2 2024 for weather-related damage at the Lewiston facility.
Investor Verification Checklist
- Debt Servicing: Verify the company's ability to meet mandatory prepayment requirements (50% of quarterly excess cash flows) under the new Term Credit Agreement.
- Integration Synergies: Monitor the realization of cost savings and revenue growth from the Augusta acquisition against the $20.3 million in acquisition/integration costs incurred YTD.
- Divestiture Finality: Confirm the final purchase price adjustments for the $1.06 billion tissue sale and any retained liabilities.
- Margin Recovery: Track gross margin trends to determine if price decreases and maintenance outage costs are temporary or indicative of a structural shift.
- Covenant Compliance: Review future leverage ratios to ensure compliance with the maximum consolidated leverage ratio (4.50x to 1.00 initially) and minimum current ratio (1.25 to 1.00) covenants.